Aescap 2.0: Open for new investors
Aescap invests in high-growth companies dedicated to develop and market highly innovative medical treatments. It typically invests in those companies.
Aescap’s latest fund, Aescap 2.0, invests in public biotech companies that are de-risked from a technology and finance perspective. The Fund’s objective is to enable the development of next generation medicine and make an annual average net return of 20%+ to its investors in parallel.
The fund’s ability to outperform the market is the result of a focused investment strategy, investing in around 18 biotech companies at a time, based on fundamental company analyses and a constant dialogue with their management. Another important pillar under our success is the multi-disciplinary set-up of our team, with most team members having been part of the healthcare industry for over 25 years.
Investors in Aescap 2.0 can join or exit the fund on a monthly basis. The fund is a so called fund for joint account. The minimum investment amount in the fund is € 0.5 million. Please feel free to give us a call at +31 20 570 29 40 or send an email to firstname.lastname@example.org to receive more information.
Best regards on behalf of the Aescap team,
Aescap Medical Investments B.V.
Patrick J.H. Krol